Broxyquinoline

Summary

Broxyquinoline (CHEMBL223448) is an approved small molecule (ATC G01AC06); indicated across 1 condition including amebiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AC06 (+2 more)
• Indications: 1 condition
• Chemistry: 302.95 Da · C9H5Br2NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL223448
Name	Broxyquinoline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2453
ATC	G01AC06, A07AX01, P01AA01
Molecular formula	C9H5Br2NO
Molecular weight	302.95
InChIKey	ZDASUJMDVPTNTF-UHFFFAOYSA-N

SMILES: C1=CC2=C(C(=C(C=C2Br)Br)O)N=C1

IUPAC name: 5,7-dibromoquinolin-8-ol

Also known as: Broxiquinolina, Broxyquinoline, NSC-1810, Starogyn, SID26748318, SID93576738, SID144204891, BROXYQUINOLINE, SID170466167

Patent coverage: 268 distinct patent families (855 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 837 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lysine-specific demethylase 4E, Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Survival motor neuron protein, Menin/Histone-lysine N-methyltransferase MLL, Catechol O-methyltransferase, Heat shock protein HSP 90-alpha, Cellular tumor antigen p53, Metallo-beta-lactamase type 2.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P51450	6.55	Potency	281.8	nM	CHEMBL_ACT_4999442
TDP1	6.2	Potency	631	nM	CHEMBL_ACT_3931372
HSP90AA1	6.16	AC50	700	nM	CHEMBL_ACT_7446716
USP2	5.4	Potency	3981	nM	CHEMBL_ACT_4727780
P22734	5.39	IC50	4074	nM	CHEMBL_ACT_14676312
C7C422	5.38	IC50	4200	nM	CHEMBL_ACT_25632619
HTT	5.1	Potency	7943	nM	CHEMBL_ACT_3749338
TP53	5.1	Potency	7943	nM	CHEMBL_ACT_4846268

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
amebiasis	4	MONDO:0005644	EFO:0007144

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).